AstraZeneca touts PhIII event-free survival win with Imfinzi
On the heels of Merck reporting a Phase III win with Keytruda before and after surgery in non-small cell lung cancer (NSCLC), AstraZeneca is announcing …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.